A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy

N/AUnknownNCT04520646

Huashan Hospital10 enrolled

Overview

Acromegaly is a disease characterized by excess growth hormone(GH) and insulin like growth factor(IGF)-1. Pituitary GH secreting adenoma is the major cause of acromegaly. Acromegalic cardiomyopathy is one of the leading causes of death in acromegalic patients. No efficient medicine is available for acromegalic cardiomyopathy until now and there were limited studies. Empagliflozin is proved to decrease the risk of heart failure in diabetic patients and independent of blood glucose control. We planed to evaluate the structure of heart by MRI before and after 6 months treatment with empagliflozin in acromegalic patients to investigate the effect of empagliflozin on acromegalic cardiomyopathy.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Acromegaly Cardiomyopathies

Interventions

empagliflozin of 10mg/day is added on the basis of primary care

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with pituitary GH adenomas confirmed by surgery active acromegalic patients although treated with surgery,radiation therapy and somatostatin analogs Exclusion Criteria: * patients with contraindications to empagliflozin pregnant patients patients with poor control of hypertension(SBP\>150mmHg or DBP\>95mmHg patients with contraindications to MRI

Locations (1)

Huashan Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Left ventricular mass index

the changes in left ventricular mass index by heart MRI

Time frame: 6 months

Central Contacts

Cuiyun Wu

CONTACT

+86(21)52888045 mhe2004@263.net

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.